Paper: Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM)
Program: Oral and Poster Abstracts Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III Hematology Disease Topics & Pathways: Adult, Biological, multiple myeloma, antibodies, Di seases, Therapies, Plasma Cell Disorders, Study Population, Lymphoid Malignancies Niels W.C.J. Van De Donk 1, Sonja Zweegman, MD, PhD 2, Jesus F. San-Miguel, MD, PhD 3, Meletios A Dimopoulos 4, Michele Cavo 5 *, Kenshi Suzuki, MD, PhD 6, Cyrille Touzeau 7 *, Saad Z. Usmani, MD, MBBS, MBA 8, Aurore